Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment

Data from 2 prospective, open-label studies (n=25) suggest that clinically used starting dose of selexipag need no dose adjustments in patients with mild/moderate hepatic impairment (HI) or severe renal impairment, although no conclusion could be reached for those with severe HI.

Selexipag is a non-prostanoid PGI2 receptor agonist.

 

The EU has issued a positive opinion for marketing authorisation for long-term treatment of pulmonary arterial hypertension in adults with WHO functional class II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.